Chiral Chromatography Columns Market: as the FDA and EMA have made single-enantiomer approval the default for new small-molecule drugs, chiral purity testing shifts from a specialist analytical exercise into a mandatory checkpoint at every stage of the drug development pipeline, so pharmaceutical and contract manufacturing budgets treat chiral separation infrastructure as a fixed cost of doing business, and vendors that combine broad chiral stationary phase chemistry libraries with faster, lower-solvent separation platforms are capturing share from single-technique specialists.

The global chiral chromatography columns market size was USD 890.0 Million in 2025 and is expected to register a revenue CAGR of 8.8% during the forecast period. Market revenue growth is driven by factors such as the sustained FDA and EMA regulatory preference for single-enantiomer new drug approvals, the conversion of contract development and manufacturing organisations from normal-phase chiral HPLC to faster supercritical fluid chromatography platforms, and the expansion of chiral stationary phase chemistry libraries that shorten method development time. The first driving factor is the regulatory environment that has made chiral purity a default consideration in essentially all new small-molecule drug development. Academic analysis of new drug approvals found that the European Medicines Agency has approved no racemic drugs since 2016, and the FDA has averaged only one racemic drug approval per year since its 1992 chirality policy, meaning more than half of pharmaceuticals on the market today are chiral compounds requiring enantiomeric purity control at every development stage. The second driving factor is the technology shift from normal-phase liquid chromatography toward supercritical fluid chromatography platforms that use carbon dioxide as the primary mobile phase. Waters Corporation reported that its pharmaceutical-market liquid chromatography sales returned to growth in 2025, with instrument system sales increasing as more contract manufacturers converted normal-phase chiral methods to solvent-efficient SFC platforms. The third driving factor is the continued expansion of chiral stationary phase chemistries that reduce method development time. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single chiral stationary phase chemistry, once validated for a given class of molecules, widens its own revenue base as the same phase gets re-ordered across a drug’s entire development lifecycle, from early candidate screening through commercial batch release testing, without a new instrument qualification for each stage. Once a laboratory validates a specific chiral column chemistry for a compound class, every subsequent batch, method transfer, or line extension re-orders the same column family rather than re-screening from scratch, so the value of a widely validated chiral stationary phase compounds as more molecules in a compound class move through the pipeline behind it. As a result, demand and revenue share are concentrating around the chiral stationary phase families with the broadest validated compound coverage, and the forecast tilts toward established polysaccharide-based phase families rather than narrow, single-application specialty phases. For instance, in June 2025, Daicel Chiral Technologies, United States, launched CHIRALPAK IJ, a new immobilized chiral selector extending its established polysaccharide-based CHIRALPAK and CHIRALCEL families, one of more than a dozen selector chemistries the same product line now offers without requiring customers to qualify a new column brand. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the regulatory environment that has made single-enantiomer development the default pathway for new small-molecule drugs. A racemic drug can no longer be registered as a new chemical entity without specific scientific justification under the FDA’s 1992 chirality policy, and this default works only if chiral analytical infrastructure is available at every development stage, so regulatory preference and chiral separation capacity have grown together rather than independently. Academic analysis of FDA and EMA approvals from 2013 to 2022 found the EMA has approved no racemic drugs since 2016 and the FDA has averaged only one racemic approval per year, with approximately 56% of marketed pharmaceuticals now chiral compounds requiring enantiomeric purity control from candidate screening through commercial release testing. The recent record shows the pace. In June 2025, Daicel Chiral Technologies launched CHIRALPAK IJ, a new immobilized chiral selector, and in January 2025 Waters Corporation expanded its MaxPeak Premier column portfolio with preparative columns introduced at the WCBP 2025 regulatory science conference in Washington, DC. The effect on the market is that chiral separation capacity has become a fixed infrastructure requirement rather than a discretionary analytical purchase for any organisation developing small-molecule drugs. These are some of the key factors driving revenue growth of the market.

The second driver is the technology migration from normal-phase liquid chromatography to supercritical fluid chromatography for chiral separations. SFC replaces most of the organic mobile phase with supercritical or subcritical carbon dioxide, and this substitution works only if chiral stationary phases are validated for compatibility with CO2-based mobile phases, so stationary phase chemistry development and SFC instrument adoption have advanced together. Waters Corporation reported that pharmaceutical-market liquid chromatography sales returned to growth in 2025, with instrument system sales increasing as contract manufacturers converted normal-phase chiral methods to SFC platforms that cut both separation time and solvent cost. Daicel’s polysaccharide-based CHIRALPAK and CHIRALCEL stationary phases, compatible with both HPLC and SFC mobile phase systems, remain the most widely used chiral chromatography products globally, recognised for durability and separation performance across both analytical and preparative process-scale applications. The effect on the market is that preparative SFC system placements are becoming the primary growth channel for chiral separation capital equipment spending among CDMOs and large pharmaceutical manufacturers. These are some of the key factors driving revenue growth of the market.

“Daicel’s CHIRALPAK and CHIRALCEL polysaccharide-based families remain the most widely used chiral stationary phases in the world, spanning more than a dozen selector chemistries that customers can screen without qualifying a new column brand for each new compound class.”

The third driver is the expansion of chiral stationary phase chemistry libraries that reduce the time required to identify a viable separation method. Method development for a novel chiral compound requires screening across multiple stationary phase chemistries and mobile phase conditions, and a broader validated chemistry library increases the odds that an early screen finds a working method without escalating to custom development, so library breadth directly compresses the most labour-intensive step in the chiral workflow. Phenomenex expanded its Lux polysaccharide chiral column line with a new particle size option for its Amylose-1 selector, broadening method scalability from analytical screening through preparative purification within a single chemistry family. Daicel’s introduction of new immobilized selectors, including CHIRALPAK IJ in 2025, extends solvent compatibility beyond what coated-phase predecessors could support, widening the conditions under which a single column can be screened. The effect on the market is that chiral method development cycle times are compressing, lowering the effective cost of adopting chiral analytical methods for smaller drug development programmes. These are some of the key factors driving revenue growth of the market.

However, the chiral chromatography columns market faces severe adoption constraints from the high unit cost of specialised chiral stationary phase columns and the time-intensive, skilled-labour-dependent nature of chiral method development. Because chirally selective stationary phase materials require a substantially more specialised manufacturing process than standard achiral packing materials, reflecting the precision synthesis required to bond or immobilise a chiral selector onto a silica support, chiral columns carry a meaningful cost premium over achiral HPLC columns that creates a real barrier for smaller biotechnology companies and academic research laboratories operating with constrained analytical equipment budgets. Method development complexity is a second constraint, because identifying a viable separation method for a specific enantiomeric pair requires systematic screening across multiple chiral stationary phase chemistries and mobile phase conditions, and this screening remains a specialised analytical chemistry exercise rather than a standardised workflow, creating a skilled-labour bottleneck that constrains throughput at contract testing laboratories during periods of high drug development pipeline activity. The capital cost of preparative-scale supercritical fluid chromatography systems used for commercial chiral API purification is the third constraint, since this equipment represents a significant capital investment that limits adoption to larger pharmaceutical manufacturers and well-capitalised contract development and manufacturing organisations, so smaller-scale drug developers continue to rely on outsourced preparative separation services rather than in-house capacity. These factors substantially limit chiral chromatography columns market growth over the forecast period.

Based on column type, the global chiral chromatography columns market is segmented into pre-packed analytical columns, preparative and process-scale columns, and empty user-packed columns. Pre-packed analytical columns hold the largest revenue share, because they serve the highest-frequency use case of method development and quality control screening across every stage of the drug development pipeline, which suits the recurring, per-project purchasing pattern of pharmaceutical and CDMO laboratories. Empty user-packed columns remain established among larger laboratories running high sample volumes, and they are cheaper per gram of stationary phase at scale, but they cannot match the convenience and lot-to-lot consistency of pre-packed formats for routine method development. Preparative and process-scale columns are expected to register rapid revenue growth in the global chiral chromatography columns market over the forecast period, driven by CDMO and pharmaceutical manufacturer investment in supercritical fluid chromatography purification capacity, which is why Waters Corporation and Agilent Technologies continue expanding their preparative column and system portfolios.

Liquid chromatography technique is expected to account for a significantly large revenue share in the global chiral chromatography columns market during the forecast period

Based on technique, the global chiral chromatography columns market is segmented into liquid chromatography, supercritical fluid chromatography, gas chromatography, and thin-layer chromatography. Liquid chromatography holds the largest revenue share, because HPLC and UHPLC remain the most common analytical technique used to control enantiomeric purity throughout pharmaceutical development, which suits its broad instrument installed base across pharmaceutical quality control laboratories. Supercritical fluid chromatography is expected to register the fastest revenue growth rate in the global chiral chromatography columns market over the forecast period, driven by CDMO conversion from normal-phase HPLC to faster, lower-solvent SFC platforms, which is why Waters Corporation and Agilent Technologies are expanding their preparative SFC system portfolios.

Based on stationary phase, the global chiral chromatography columns market is segmented into polysaccharide-based phases, macrocyclic and protein-based phases, and crown ether and other specialty phases. Polysaccharide-based phases hold the largest revenue share, because Daicel’s CHIRALPAK and CHIRALCEL families offer the broadest validated compound coverage of any chiral stationary phase chemistry, which suits laboratories seeking to minimise the number of column chemistries they must qualify and maintain. Macrocyclic and protein-based phases are expected to register rapid revenue growth in the global chiral chromatography columns market over the forecast period, driven by their effectiveness on compound classes that polysaccharide phases resolve poorly, which is why Regis Technologies and Phenomenex continue expanding their macrocyclic selector offerings for pharmaceutical customers.

Based on regional analysis, the chiral chromatography columns market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of pharmaceutical and biotechnology drug development activity subject to FDA chirality policy, and because Waters Corporation and Agilent Technologies, two of the largest chromatography instrument and column manufacturers globally, are headquartered and manufacture extensively in the country. Waters Corporation’s pharmaceutical-market liquid chromatography sales returned to growth in 2025, reinforcing the scale of United States pharmaceutical capital investment in chiral separation infrastructure. The concentration of chiral method development expertise and CDMO capacity in the United States also means new chiral stationary phase chemistries are often adopted in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national chiral chromatography markets within Europe. The European Medicines Agency’s zero-racemate approval record since 2016 sustains structural demand for chiral separation infrastructure across the region’s large pharmaceutical manufacturing base, and Daicel Chiral Technologies Europe maintains dedicated regional supply and application support from its Illkirch, France facility. The result is steady rather than rapid growth, shaped more by the region’s already-mature chiral analytical infrastructure than by unmet demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and India represent the three largest national chiral chromatography markets within the region. Japan is the home market of Daicel Corporation, the global leader in chiral stationary phase manufacturing, while China’s and India’s expanding generic and specialty pharmaceutical manufacturing base is driving new chiral quality control infrastructure investment, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national chiral chromatography markets within the region. Generic pharmaceutical manufacturers in both countries are expanding chiral quality control capacity to support export-oriented production, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised chromatography instruments and columns that Latin American laboratories depend on through 2026, slowing adoption beyond the region’s main pharmaceutical manufacturing centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and Israel represent the primary commercial chiral chromatography markets within the region. Israel is the most established chiral chromatography market on the continent given its concentrated pharmaceutical and biotechnology research base, while the wider Gulf states are still building generic pharmaceutical manufacturing and associated chiral quality control capacity from scratch.